Screener
Gilead Sciences GILD Other HIV — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions) | Three Months Ended June 30, 2026 / U.S. | Three Months Ended June 30, 2026 / Europe | Three Months Ended June 30, 2026 / Rest of World | Three Months Ended June 30, 2026 / Total | Three Months Ended June 30, 2025 / U.S. | Three Months Ended June 30, 2025 / Europe | Three Months Ended June 30, 2025 / Rest of World | Three Months Ended June 30, 2025 / Total |
|---|---|---|---|---|---|---|---|---|
| Odefsey | 171 | 58 | 10 | 239 | 221 | 66 | 11 | 298 |
| Symtuza - Revenue share(1) | 105 | 30 | 3 | 138 | 88 | 33 | 3 | 124 |
| Yeztugo | 223 | — | 9 | 232 | 15 | — | — | 15 |
| Other HIV(2) | 23 | 24 | 10 | 56 | 50 | 33 | 9 | 92 |
| Total HIV | 4,659 | 640 | 393 | 5,693 | 4,096 | 624 | 368 | 5,088 |
| Liver Disease | ||||||||
| Livdelzi | 147 | 20 | — | 167 | 74 | 4 | — | 78 |
| Sofosbuvir/Velpatasvir(3) | 142 | 81 | 80 | 303 | 184 | 81 | 76 | 342 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's other HIV — total revenues?
- Gilead Sciences (GILD) reported other HIV — total revenues of $56M in Q2 2026.
- How has Gilead Sciences's other HIV — total revenues changed year-over-year?
- Gilead Sciences's other HIV — total revenues decreased by 39.1% year-over-year, from $92M to $56M.
- What is the long-term trend for Gilead Sciences's other HIV — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's other HIV — total revenues has grown at a -2.9% compound annual growth rate (CAGR), from $530M to $485M.
- What does other HIV — total revenues mean?
- This metric represents the total revenue generated from the company's secondary or legacy HIV product portfolio, excluding primary flagship therapies. It captures the financial performance of niche treatments, older formulations, or ancillary products within the HIV therapeutic area. Monitoring this segment helps investors assess the lifecycle management of the company's broader infectious disease franchise and the contribution of non-core assets to total HIV-related income.
Ask your AI about Gilead Sciences's other hiv — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude